Curated News
By: NewsRamp Editorial Staff
October 17, 2024
Stonegate Capital Partners Initiates Coverage on Sirona Biochem Corp (TSX-V:SBM)
Discuss on Reddit
Substack
TelegramTLDR
- Sirona Biochem Corp (TSX-V:SBM) targets profitability by 2025, with expected revenue from Allergan Aesthetic and the commercialization of GlycoProteMim™ set to drive growth.
- GlycoProteMim™ is a potential standout in the premium skincare market, with Sirona's partnerships placing it in a strong position to capture market share.
- Sirona Biochem Corp's GlycoProteMim™ has the potential to make the world a better place by providing innovative products in the skincare industry.
- Stonegate Capital Partners initiates coverage on Sirona Biochem Corp (TSX-V:SBM), with the potential of GlycoProteMim™ and its partnerships making it an interesting investment opportunity.
Impact - Why it Matters
This news matters as it highlights the potential growth and profitability of Sirona Biochem Corp, offering insights into the company's position in the skincare industry and its future prospects.
Summary
Stonegate Capital Partners has initiated coverage on Sirona Biochem Corp (TSX-V:SBM), highlighting the potential of GlycoProteMim™ in the premium skincare market and Sirona's expected profitability by 2025. The company's partnerships position it to capture market share in the global skincare industry.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Stonegate Capital Partners Initiates Coverage on Sirona Biochem Corp (TSX-V:SBM)
